Limelight Bio emerges with $75m to develop next generation gene therapies to overcome limitations of current treatments

Founded in 2017, Limelight Bio has developed proprietary technologies, advanced targets and leading drug candidates designed to overcome key limitations of current gene therapy and gene editing approaches.

The post Limelight Bio emerges with $75m to develop next generation gene therapies to overcome limitations of current treatments appeared first on Pharmaceutical Business review.

FerGene’s phase 3 NMIBC study of Nadofaragene Firadenovec meets primary endpoint

FKD Therapies Oy (FKD) has led the development and regulatory filing of nadofaragene firadenovec, which has been studied in 33 centers across the U.S. in collaboration with the

The post FerGene’s phase 3 NMIBC study of Nadofaragene Firadenovec meets primary endpoint appeared first on Pharmaceutical Business review.

Meitheal Pharmaceuticals announces FDA approval of Enoxaparin Sodium Injection, USP

Meitheal licenses Enoxaparin Sodium Injection exclusively through its partnership with Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (NKF), its majority shareholder. Enoxaparin had annual sales of approximately $616M in

The post Meitheal Pharmaceuticals announces FDA approval of Enoxaparin Sodium Injection, USP appeared first on Pharmaceutical Business review.